05Sep 2022
High‐dose, high‐frequency ustekinumab therapy for patients with severe hidradenitis suppurativa

High‐dose, high‐frequency ustekinumab therapy for patients with severe hidradenitis suppurativa

In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.

  • #dermatology

Like

Save

Share